Loading...
XNAS
IONS
Market cap12bUSD
Dec 05, Last price  
81.68USD
1D
-0.16%
1Q
33.40%
Jan 2017
70.77%
Name

Ionis Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:IONS chart
P/E
—
P/S
18.41
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.91%
Rev. gr., 5y
-8.89%
Revenues
705m
-10.48%
40,133,00024,532,00069,621,000107,190,000121,600,000108,473,00099,086,000102,049,000147,285,000214,161,000283,703,000346,620,000507,666,000599,674,0001,123,000,000729,000,000810,000,000587,000,000787,647,000705,138,000
Net income
-454m
L+23.92%
-72,401,000-45,903,000-10,994,000-11,963,000155,066,000-61,251,000-84,801,000-65,478,000-60,644,000-38,984,000-88,278,000-86,556,000-5,970,000273,741,000294,000,000-487,000,000-29,000,000-270,000,000-366,286,000-453,897,000
CFO
-501m
L+62.90%
-61,741,000-53,225,00036,094,000212,031,000-108,441,000-63,593,000-114,801,0001,876,00063,493,0006,285,00021,125,000-112,105,000174,149,000602,888,000345,720,00035,892,00030,799,000-274,370,000-307,513,000-500,947,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
URL
https://www.ionispharma.com/
IPO date
May 17, 1991
Employees
796
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT